Gefitinib Completed Phase 2 Trials for Salivary Gland Cancers Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00509002Iressa Study in Patients With Salivary Gland Cancer